We are live on ! Find out more
XBIT icon

XBiotech

49 hedge funds and large institutions have $35.1M invested in XBiotech in 2016 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 24 increasing their positions, 11 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

118% more repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 11

33% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 3

10.69% more ownership

Funds ownership: 0%10.69% (+11%)

2% more funds holding

Funds holding: 4849 (+1)

19% less capital invested

Capital invested by funds: $43.6M → $35.1M (-$8.5M)

45% less call options, than puts

Call options by funds: $525K | Put options by funds: $952K

Holders
49
Holders Change
+1
Holders Change %
+2.08%
% of All Funds
1.23%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
4
Increased
24
Reduced
11
Closed
3
Calls
$525K
Puts
$952K
Net Calls
-$427K
Net Calls Change
+$363K
Name Holding Trade Value Shares
Change
Change in
Stake
Simplex Trading
51
Simplex Trading
Illinois
-$54.4K -4,086 Closed
MAM
52
Meeder Asset Management
Ohio
+$200 +15 New

XBIT Hedge Fund Activity: Q4 2016 in Review

49 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in XBiotech (XBIT) for Q4 2016, worth a combined $35.1M — down 19% from $43.6M a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new XBIT positions and 3 closed out — a net gain of 1 holder — while 24 added to existing stakes and 11 trimmed.

The largest buyer was BlackRock Fund Advisors, adding an estimated $1.31M. The largest seller was Cadian Capital Management, exiting entirely with an estimated $1.88M sold.

  • 49 institutional investors held XBiotech (XBIT) as of Q4 2016, up from 48 in Q3 2016.
  • Funds reported $35.1M of XBiotech stock for Q4 2016, down 19% quarter-over-quarter.
  • 4 funds opened new XBiotech positions in Q4 2016 and 3 closed out, a net change of +1 holder.
  • The largest XBiotech buyer in Q4 2016 was BlackRock Fund Advisors, an estimated $1.31M added.
  • The largest XBiotech seller in Q4 2016 was Cadian Capital Management, an estimated $1.88M sold.

Based on aggregated 13F filings for Q4 2016.